Profile
Thomas R.
Beck was the founder of Dimension Therapeutics, Inc. founded in 2013, where he held the position of President, Chief Executive Officer & Director.
He also held former positions as Chairman & Chief Executive Officer of CytoMed, Inc., Chairman of Xilio Therapeutics, Inc., Director of Mersana Therapeutics, Inc. and Topaz Pharmaceuticals, Inc., Director of Vicept Therapeutics, Inc., Director & Chief Medical Officer of Promentis Pharmaceuticals, Inc., Director & Head-Research and Development of Symbiomix Therapeutics LLC, Director-Global Research & Development of UCB Pharma, Inc., Director of NeuroTherapeutics Pharma, Inc., and Director of Adagene, Inc. He was also President & Chief Operating Officer of Dyax Corp.
from 2005 to 2007, President of Enzytech, Inc., Vice President-Business & Clinical Development of Smith Kline & French Laboratories Ltd., Executive Partner of Impresa Management LLC, and Assistant Professor at Temple University School of Medicine.
Dr. Beck received his undergraduate degree from Yale University and his doctorate from Cornell University.
Former positions of Thomas R. Beck
| Companies | Position | End |
|---|---|---|
| DYAX CORP. | President | 2007-03-02 |
Promentis Pharmaceuticals, Inc.
 Promentis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Promentis Pharmaceuticals, Inc. engages in the develop of novel compounds for the treatment of schizophrenia and other central nervous system disorders. The firm's drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other disesses. It discovers, develops and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. The company was founded by David A. Baker and John Mantsch in 2007 and is headquartered in Milwaukee, WI. | Chief Tech/Sci/R&D Officer | - |
| XILIO THERAPEUTICS, INC. | Chairman | - |
Symbiomix Therapeutics LLC
 Symbiomix Therapeutics LLC BiotechnologyHealth Technology Symbiomix Therapeutics LLC develops medicines for women’s health infections and related diseases. It offers SYM-1219, a drug that contains secnidazole that facilitate administration as a single-dose oral therapy for various women's health infections including bacterial vaginosis. The company was founded by Jack Roberts, Steve Pomerantz and Joseph L. Amprey III in 2012 and is headquartered in Newark, NJ. | Chief Tech/Sci/R&D Officer | - |
| Temple University School of Medicine | Corporate Officer/Principal | - |
Training of Thomas R. Beck
| Yale University | Undergraduate Degree |
| Cornell University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| MERSANA THERAPEUTICS, INC. | Health Technology |
| ADAGENE INC. | Health Technology |
| XILIO THERAPEUTICS, INC. | Health Technology |
| Private companies | 12 |
|---|---|
Dyax Corp.
 Dyax Corp. Pharmaceuticals: MajorHealth Technology Dyax Corp. engages in discovery, development and commercialization of novel biotherapeutics. The company was founded by Henry E. Blair in 1989 and is headquartered in Burlington, MA. | Health Technology |
Topaz Pharmaceuticals, Inc.
 Topaz Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Topaz Pharmaceuticals, Inc. operates as a pharmaceutical company which focuses on developing and commercializing treatments for the pediatric and dermatology markets. Its lead investigational product is a topical cream formulation of ivermectin which is under development. The firm provides medicines for the treatment of head lice, acne and infections, as well as vaccines against childhood diseases. The company was founded by Donald P. Beeman and Nicholas U. Spring in 2005 and is headquartered in Horsham, PA. | Health Technology |
Vicept Therapeutics, Inc.
 Vicept Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Vicept Therapeutics Inc. develops dermatologic therapeutic products. The firm develops topical agents for the treatment and prevention of a number of medical and cosmetic indications including bruising of the skin. The company was founded on July 1, 2009 by Neal Walker, Stewart D. Shanler, and Christopher V. Powala and is headquartered in Malvern, PA. | Health Technology |
Promentis Pharmaceuticals, Inc.
Promentis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Promentis Pharmaceuticals, Inc. engages in the develop of novel compounds for the treatment of schizophrenia and other central nervous system disorders. The firm's drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other disesses. It discovers, develops and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. The company was founded by David A. Baker and John Mantsch in 2007 and is headquartered in Milwaukee, WI. | Health Technology |
Symbiomix Therapeutics LLC
Symbiomix Therapeutics LLC BiotechnologyHealth Technology Symbiomix Therapeutics LLC develops medicines for women’s health infections and related diseases. It offers SYM-1219, a drug that contains secnidazole that facilitate administration as a single-dose oral therapy for various women's health infections including bacterial vaginosis. The company was founded by Jack Roberts, Steve Pomerantz and Joseph L. Amprey III in 2012 and is headquartered in Newark, NJ. | Health Technology |
CytoMed, Inc.
 CytoMed, Inc. Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., CytoMed, Inc. is a company that develops therapeutics for cancer treatment. The company is based in Cambridge, MA. CytoMed was acquired by LeukoSite, Inc., part of Takeda Pharmaceutical Co., Ltd. from December 22, 1999 on February 12, 1999 for $19.29 million. | Health Technology |
Enzytech, Inc.
 Enzytech, Inc. Pharmaceuticals: MajorHealth Technology Enzytech, a biopharmaceutical company founded in 1987, developed mechanisms to deliver smaller doses of drugs specifically to their targets. | Health Technology |
UCB Pharma, Inc.
 UCB Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services UCB Pharma, Inc. provides research, development & commercialisation of pharmeceutical and biotechnology products. Its products are Keppra, Xyzal, Atarax, Lortab, Dipentum, and Tussionex. UCB Pharma develops small and large molecule treatments for a variety of diseases and ailemts. The company was founded by Emmanuel Janssen in 1928 and is headquartered in Smyrna, GA. | Commercial Services |
NeuroTherapeutics Pharma, Inc.
 NeuroTherapeutics Pharma, Inc. Pharmaceuticals: MajorHealth Technology NeuroTherapeutics Pharma, Inc. is a biopharmaceutical company focused on developing therapies for diseases associated with central nervous system hyper-excitability. It is developing compounds that decrease or eliminate aberrant excitatory discharges by working through a new mechanism of action. The firm's proprietary molecules target a novel molecular site that will create a pipeline of potential new treatments for multiple CNS disorders. The company's lead compound, NTP-2014, has exhibited excellent efficacy results in multiple preclinical models of epilepsy, acute and neuropathic pain. NeuroTherapeutics Pharma was founded in 2006 and is headquartered in Chicago, IL. | Health Technology |
Smith Kline & French Laboratories Ltd.
 Smith Kline & French Laboratories Ltd. Pharmaceuticals: MajorHealth Technology Smith Kline & French Laboratories Ltd. manufactures pharmaceutical products. The company is headquartered in Brentford, the United Kingdom. | Health Technology |
Dimension Therapeutics, Inc.
 Dimension Therapeutics, Inc. BiotechnologyHealth Technology Dimension Therapeutics, Inc. engages in the development of novel treatments for rare diseases. Its activities include discoveries and development of therapeutic products for people living with rare diseases associated wit the liver and caused by genetic mutations. The company was founded by Ben Auspitz in June 20, 2013 and is headquartered in Cambridge, MA. | Health Technology |
Impresa Management LLC
 Impresa Management LLC Investment ManagersFinance Impresa Management LLC(Impresa Management) is a Private Equity/Venture Capital firm, a subsidiary of Devonshire Investors LLC founded in 1946.The firm is headquartered in Boston. | Finance |
- Stock Market
- Insiders
- Thomas R. Beck
